Abstract
In silico methods have been used to identify five different classes of compounds as inhibitors of the essential Plasmodium falciparum enzyme lactate dehydrogenase (LDH). The molecules were assayed for in vitro antimalarial activity in both cell- and enzyme-based inhibition models. 5-Bromo-2-hydroxypyridine-3-carboxylic acid 19 is the most active with IC50 of 3.5 nM for chloroquine sensitive and 5 nM for resistant strains of Plasmodium falciparum, compared to 11 nM and 100 nM for the standard chloroquine. In LDH-enzyme inhibition assays the leading compounds are 5, 10, 18 and 19. Docking studies and the 3D-QSAR technique - CoRIA have been used to identify key binding elements between the molecules and residues in the LDH active site. A bifurcated salt bridge that associates the carboxylate group on the molecules with the guanidino group in the side chain of both Arg109 and Arg171 along with π-stack of the heterocycle with the pyridine ring of the cofactor NAD+, are the prime interactions. In silico ADME/toxicity studies also suggest these molecules have favorable pharmacokinetic and toxicity profiles.
Keywords: Antimalarial agents, CoRIA, docking, lactate dehydrogenase, Plasmodium falciparum, QSAR, Malaria
Anti-Infective Agents
Title: Molecular Modeling Studies, Synthesis and Biological Evaluation of Novel Plasmodium falciparum Lactate Dehydrogenase (pfLDH) Inhibitors
Volume: 10 Issue: 1
Author(s): Premlata K. Ambre, Raghuvir R. S. Pissurlenkar, Ashish S. Jagyasi, Ritesh A. Fule, Vijay Khedkar, Chandrashekar R. Barhate, Livia Vivas, Abhai K. Tripathi, David Sullivan, Richard Birkinshaw, R. Leo Brady, Krishna Iyer and Evans C. Coutinho
Affiliation:
Keywords: Antimalarial agents, CoRIA, docking, lactate dehydrogenase, Plasmodium falciparum, QSAR, Malaria
Abstract: In silico methods have been used to identify five different classes of compounds as inhibitors of the essential Plasmodium falciparum enzyme lactate dehydrogenase (LDH). The molecules were assayed for in vitro antimalarial activity in both cell- and enzyme-based inhibition models. 5-Bromo-2-hydroxypyridine-3-carboxylic acid 19 is the most active with IC50 of 3.5 nM for chloroquine sensitive and 5 nM for resistant strains of Plasmodium falciparum, compared to 11 nM and 100 nM for the standard chloroquine. In LDH-enzyme inhibition assays the leading compounds are 5, 10, 18 and 19. Docking studies and the 3D-QSAR technique - CoRIA have been used to identify key binding elements between the molecules and residues in the LDH active site. A bifurcated salt bridge that associates the carboxylate group on the molecules with the guanidino group in the side chain of both Arg109 and Arg171 along with π-stack of the heterocycle with the pyridine ring of the cofactor NAD+, are the prime interactions. In silico ADME/toxicity studies also suggest these molecules have favorable pharmacokinetic and toxicity profiles.
Export Options
About this article
Cite this article as:
K. Ambre Premlata, R. S. Pissurlenkar Raghuvir, S. Jagyasi Ashish, A. Fule Ritesh, Khedkar Vijay, R. Barhate Chandrashekar, Vivas Livia, K. Tripathi Abhai, Sullivan David, Birkinshaw Richard, Leo Brady R., Iyer Krishna and C. Coutinho Evans, Molecular Modeling Studies, Synthesis and Biological Evaluation of Novel Plasmodium falciparum Lactate Dehydrogenase (pfLDH) Inhibitors, Anti-Infective Agents 2012; 10 (1) . https://dx.doi.org/10.2174/2211362611201010055
DOI https://dx.doi.org/10.2174/2211362611201010055 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
Call for Papers in Thematic Issues
An Overview of Drugs for Multiple Targets and Variants of SARS-CoV-2 Through Artificial Intelligence, Machine Learning, Deep Learning, and Experimental Analysis
The emergence and rapid evolution of SARS-CoV-2 variants have posed significant challenges in the ongoing fight against the COVID-19 pandemic. The development of effective treatments for multiple viral targets and variants demands innovative approaches, including artificial intelligence (AI), machine learning (ML), and deep learning (DL) techniques. This special issue aims ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multidrug Resistance Phenotype Mediated by the P-Glycoprotein-Like Transporter in Leishmania: A Search for Reversal Agents
Current Drug Targets Biodiversity as a Source of Bioactive Compounds Against Snakebites
Current Medicinal Chemistry Vasorelaxation Caused by Cannabinoids: Mechanisms in Different Vascular Beds
Current Vascular Pharmacology New Pharmacological Approaches in Infants with Hypoxic-Ischemic Encephalopathy
Current Pharmaceutical Design Ultrasound Assisted Synthesis of 3,4-Diyne Substituted Isocoumarin Derivatives: Identification of Potential Cytotoxic Agents
Mini-Reviews in Medicinal Chemistry Measurement and Mapping of Retinal Leakage and Retinal Thickness - Surrogate Outcomes for the Initial Stages of Diabetic Retinopathy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry Amidine-Based Bioactive Compounds for the Regulation of Arginine Metabolism
Mini-Reviews in Medicinal Chemistry Inflammatory Mechanisms in Myocardial Infarction
Current Drug Targets - Inflammation & Allergy Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes: A Systematic Literature Review
Current Cardiology Reviews Glucocorticoids and Vascular Reactivity
Current Vascular Pharmacology Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Molecular Targeted Therapy in Enteropancreatic Neuroendocrine Tumors: From Biology to Clinical Practice
Current Medicinal Chemistry Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets What Have We Learned from the Novel Human Cytochromes P450 Hidden in the Databases?
Current Genomics Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders
Current Pharmaceutical Design Chondroitin Sulphate Decorated Polymeric Nanoparticles: An Effective Carrier for Enhancement of Lung Cancer Targeting Capabilities of Anticancer Drug
Current Nanomedicine The Role of Cytochrome P450 in Herb-Drug Interactions
Current Pharmacogenomics Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer
Current Cancer Drug Targets